These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 12566653)

  • 1. Severe mitral valve regurgitation associated with dexfenfluramine use.
    Aurigemma GP; Ronen A; Cuénoud H; Folland ED; Meyer TE
    Cardiology; 2002; 98(4):215-7. PubMed ID: 12566653
    [No Abstract]   [Full Text] [Related]  

  • 2. Prevalence and determinants of valvulopathy in patients treated with dexfenfluramine.
    Shively BK; Roldan CA; Gill EA; Najarian T; Loar SB
    Circulation; 1999 Nov; 100(21):2161-7. PubMed ID: 10571975
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of valvular-regurgitation associated with dexfenfluramine three to five months after discontinuation of treatment.
    Weissman NJ; Tighe JF; Gottdiener JS; Gwynne JT
    J Am Coll Cardiol; 1999 Dec; 34(7):2088-95. PubMed ID: 10588229
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natural history of valvular regurgitation 1 year after discontinuation of dexfenfluramine therapy. A randomized, double-blind, placebo-controlled trial.
    Weissman NJ; Panza JA; Tighe JF; Gwynne JT
    Ann Intern Med; 2001 Feb; 134(4):267-73. PubMed ID: 11182836
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo. Sustained-Release Dexfenfluramine Study Group.
    Weissman NJ; Tighe JF; Gottdiener JS; Gwynne JT
    N Engl J Med; 1998 Sep; 339(11):725-32. PubMed ID: 9731088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence and diagnostic value of precordial murmurs for valvular regurgitation in obese patients treated with dexfenfluramine.
    Roldan CA; Gill EA; Shively BK
    Am J Cardiol; 2000 Sep; 86(5):535-9. PubMed ID: 11009272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dexfenfluramine effective in drug-resistant temporal lobe epilepsy.
    Grosso S; Farnetani MA; Berardi R; Di Bartolo R; Magi L; Morgese G; Balestri P
    Neurology; 2001 Sep; 57(6):1139-40. PubMed ID: 11571357
    [No Abstract]   [Full Text] [Related]  

  • 8. Rimonabant redux and strategies to improve the future outlook of CB1 receptor neutral-antagonist/inverse-agonist therapies.
    Ward SJ; Raffa RB
    Obesity (Silver Spring); 2011 Jul; 19(7):1325-34. PubMed ID: 21475141
    [No Abstract]   [Full Text] [Related]  

  • 9. Dexfenfluramine and heart-valve regurgitation in Chinese patients with type 2 diabetes.
    Ko GT; Chan HC; Chow CC
    Hong Kong Med J; 2003 Aug; 9(4):243-6. PubMed ID: 12904610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Operation for anorexigen-associated valvular heart disease.
    Caccitolo JA; Connolly HM; Rubenson DS; Orszulak TA; Schaff HV
    J Thorac Cardiovasc Surg; 2001 Oct; 122(4):656-64. PubMed ID: 11581595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation.
    Jick H; Vasilakis C; Weinrauch LA; Meier CR; Jick SS; Derby LE
    N Engl J Med; 1998 Sep; 339(11):719-24. PubMed ID: 9731087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of infective endocarditis associated with dental treatment and other medical interventions. National Heart Foundation.
    Ellis-Pegler RB; Hay KD; Lang SD; Neutze JM; Swinburn BA
    N Z Dent J; 1999 Sep; 95(421):85-8. PubMed ID: 10561994
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs.
    Khan MA; Herzog CA; St Peter JV; Hartley GG; Madlon-Kay R; Dick CD; Asinger RW; Vessey JT
    N Engl J Med; 1998 Sep; 339(11):713-8. PubMed ID: 9731086
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dynamic drug-induced organic mitral regurgitation during exercise echocardiography following chronic exposure to ergotamine.
    Maréchaux S; Brahim YB; Ennezat PV; Delelis F; Tribouilloy C
    Int J Cardiol; 2015; 187():106-8. PubMed ID: 25828325
    [No Abstract]   [Full Text] [Related]  

  • 15. [Image of the month. A case of aortic regurgitation association with dexfenfluramine].
    Bouffioux L; Radermecker MA; De Leval L; D'Orio V; Limet R
    Rev Med Liege; 2009 Sep; 64(9):432-3. PubMed ID: 19947311
    [No Abstract]   [Full Text] [Related]  

  • 16. The $22 billion gold rush.
    Lenzner R; Maiello M
    Mo Med; 2007; 104(1):9-11. PubMed ID: 17410817
    [No Abstract]   [Full Text] [Related]  

  • 17. Fen/Phen and valvular heart disease: the final link has now been established.
    Cheng TO
    Circulation; 2000 Dec; 102(24):E180. PubMed ID: 11113057
    [No Abstract]   [Full Text] [Related]  

  • 18. [Appetite suppressants and heart valve disorders].
    Adams C; Cohen A
    Arch Mal Coeur Vaiss; 1999 Sep; 92(9):1213-9. PubMed ID: 10533670
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of fenfluramine-derivative diet pills on cardiac valves: a meta-analysis of observational studies.
    Sachdev M; Miller WC; Ryan T; Jollis JG
    Am Heart J; 2002 Dec; 144(6):1065-73. PubMed ID: 12486432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular changes after treatment with dexfenfluramine and yohimbine in obese women measured by thoracic electrical bioimpedance.
    Waluga M; Janusz M; Karpel E; Hartleb M; Nowak A
    Boll Chim Farm; 1999; 138(7):359-63. PubMed ID: 10597657
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.